COSMIN Reporting Guideline for Studies on Measurement Properties of PROMs

What it is

The COSMIN Reporting Guideline for Studies on Measurement Properties of Patient-Reported Outcome Measures (COSMIN-RG) is a 12-item, EQUATOR-Network-listed reporting checklist published by Gagnier, Lai, Mokkink, and Terwee (Gagnier et al., Quality of Life Research, 2021) and maintained by the COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) initiative. Its purpose is narrow and specific: to make the reporting of an individual study on the measurement properties of a PROM complete and transparent, so that readers can judge what was done and reuse or appraise the evidence. It sits inside the broader COSMIN methodology, which rests on a consensus taxonomy of measurement properties — content validity, structural validity, internal consistency, cross-cultural validity/measurement invariance, reliability, measurement error, criterion validity, hypotheses-testing construct validity, and responsiveness (Mokkink et al., J Clin Epidemiol, 2010). COSMIN-RG is a reporting tool only. It is deliberately distinct from its two siblings, with which it is constantly confused: the COSMIN Risk of Bias (ROB) checklist (a methodological-quality / risk-of-bias appraisal tool) and the COSMIN guideline for systematic reviews of PROMs (Prinsen et al., Quality of Life Research, 2018), which governs how to synthesize and grade PROM evidence across studies rather than how to report one.

When to use

Apply COSMIN-RG whenever you author or referee a single primary study whose object is a measurement property of a PROM — instrument development, content-validity studies, factor-analytic/structural-validity studies, test-retest reliability, measurement error, construct or criterion validity, cross-cultural adaptation, or responsiveness. This is the relevant checklist for a journal manuscript reporting PROM psychometrics, for the measurement-property appendix of an FDA Patient-Focused Drug Development (PFDD) / Clinical Outcome Assessment (COA) submission, for an EMA dossier that relies on a PRO endpoint, and for an HTA submission where the validity of the HRQoL/utility instrument underpins the value claim. Decision rule for choosing the right COSMIN tool: reporting one measurement-property study → COSMIN-RG (this guideline); appraising the risk of bias of such studies → COSMIN ROB checklist; conducting a systematic review that selects or recommends a PROM → COSMIN-SR / Prinsen 2018. If your manuscript is a clinical RWE study that merely uses a PROM as an endpoint (rather than studying the instrument itself), COSMIN-RG is not your primary reporting guideline — STROBE/RECORD-PE govern the design, and COSMIN-evaluated evidence is what you cite to justify the instrument.

What it requires

COSMIN-RG enforces complete reporting across the elements that let a reader reconstruct and appraise a measurement-property study: (1) the construct and target population, the PROM and its versions, and the intended use (discriminative, evaluative, predictive); (2) the measurement property(ies) studied and an a-priori statement of hypotheses for construct validity and responsiveness (expected direction and magnitude of correlations / known-groups differences), so that "confirmation" is not retrofitted; (3) study design and sampling — recruitment, setting, eligibility, administration mode, and the time interval and stability assumption for test-retest reliability and responsiveness; (4) sample size and its justification; (5) statistical methods appropriate to each property (e.g., CFA/IRT fit indices for structural validity, ICC model and form for reliability, smallest detectable change / limits of agreement for measurement error, correlations and AUC for responsiveness); (6) missing-data handling and attrition across administrations, which is central because test-retest and responsiveness require repeated measurement and are vulnerable to informative loss; and (7) full results with uncertainty plus interpretability anchors (minimal important change/difference, floor/ceiling effects). Reframed for real-world data, COSMIN-RG is the discipline that makes a PROM "fit for purpose" before it is wired into a claims/EHR/registry study: it documents the instrument's provenance, the population it was validated in (and therefore the transportability of its scores), and the responsiveness evidence that justifies treating a score change as a real signal.

When NOT to use — limitations and common misapplications

- It is a reporting checklist, not a quality score or a risk-of-bias instrument. Ticking all 12 items certifies that you reported the study completely; it says nothing about whether the design was sound. Risk of bias is the job of the separate COSMIN ROB checklist — do not present a completed COSMIN-RG as evidence the PROM is valid. - Wrong sibling for the task. Using COSMIN-RG to structure a systematic review of PROMs (where Prinsen 2018 / COSMIN-SR and the GRADE-style evidence synthesis apply), or to appraise primary studies, is a scope error that senior reviewers catch immediately. - Wrong guideline for a clinical RWE study. Applying COSMIN-RG to a comparative-effectiveness or safety study that simply uses a PROM endpoint is a category error; that study reports under STROBE/RECORD-PE, with COSMIN evidence cited to support instrument choice. - Checklist-as-theater. A complete checklist on an underpowered single-administration study, or one that declares construct-validity hypotheses after seeing the correlations, is transparent reporting of a weak study — not strong evidence. - Construct/population drift. A PROM validated in one population, language, or administration mode is not automatically valid in another; reporting cross-cultural validity / measurement invariance does not waive the need to confirm it in the RWE target population.

How it maps to this catalog

COSMIN-RG governs the measurement-property evidence layer that RWE studies depend on; it does not implement causal-inference machinery (target-trial emulation, high-dimensional propensity scores, active-comparator new-user designs), and claiming it does would itself be the "checklist-as-theater" failure mode above. Map it as follows. Upstream — the studies COSMIN-RG actually reports on — are implemented by pro-development and pro-validation (instrument creation and psychometric evaluation) and pro-rwe (deploying PROs in real-world settings). Downstream — RWE analyses that consume a COSMIN-evaluated PROM — are where the measurement evidence pays off: hrqol and qaly-utility-mapping-rwe (HRQoL/utility instruments whose validity and responsiveness must be COSMIN-documented before scores drive cost-utility models), estimands-ate-att-intercurrent-events-rwe (PRO endpoints have intercurrent events — death, treatment switching, rescue therapy — that the estimand must address, and COSMIN's responsiveness/interpretability evidence defines what a meaningful change is), and missing-data-pattern-table-rwe with attrition-and-loss-to-follow-up-rwe (repeated PROM administration for test-retest and responsiveness makes informative missingness the dominant threat, which COSMIN-RG forces authors to report and which these concepts handle analytically). For evidence synthesis, route to the sibling tools, not COSMIN-RG. Applied note for claims/EHR/registry RWE: claims and most EHR data do not contain PROM scores at all, so the practical pattern is a linked or registry/primary-collection substrate; before a linked PROM endpoint is trusted, confirm via COSMIN-RG-reported evidence that the instrument was validated in a comparable population and mode (paper vs ePRO vs telephone), that a minimal important change is established, and that the responsiveness study's attrition would not bias the real-world signal.